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Background: cohort studies have demonstrated greater risk of myocardial infarction (Mi) associated with specific antiretroviral use, while meta-analyses of randomized controlled trials (rcts) have not. these differences may be due to inherent biases in the observational study design or to the limited duration of randomized trials. We conducted a new-user, active-comparator cohort study emulating an rct comparing the initiation of several antiretrovirals as part of combination antiretroviral therapy (cart) and Mi. Methods: We included north carolina (nc) Medicaid beneficiaries infected with human immunodeficiency virus between 2002 and 2008 who were previously untreated with cart. We compared hazard ratios (Hrs) and 95% confidence intervals (cis) of Mi between abacavir and tenofovir recipients, and lopinavir-ritonavir or atazanavir recipients and nonnucleoside reverse transcriptase inhibitor (nnrti) recipients. We adjusted for confounding through inverse probability weighting methods. Results: there were 3481 nc Medicaid new cart recipients who contributed 6399 person-years and experienced 38 Mi events. receiving abacavir compared with tenofovir as part of cart was associated with an increased rate of Mi (unadjusted Hr = 2.70 [95% ci = 1.24-5.91]; adjusted Hr = 2.05 [0.72-5.86]). Point estimates also suggest a relationship between receipt of atazanavir or lopinavir-ritonavir compared with an nnrti and Mi, although estimates were imprecise. Conclusions: We found an increased rate of Mi among patients initiating abacavir compared with tenofovir, although the association was decreased after confounding adjustment. Without a very large prospective comparative clinical trial, a much larger observational study of patients initiating cart would be needed to better define this apparent association.
(Epidemiology 2014; 25: 406-417) T he burden of disease among patients with human immunodeficiency virus (HiV) infection has changed since the development of potent combination antiretroviral therapy (cart). With these important new therapies, conditions not related to acquired immune deficiency syndrome (aiDS) are replacing aiDS-defining conditions as major causes of morbidity and mortality in HiV-infected patients. 1 in this context, comparative effects of specific antiretroviral medications on cardiovascular disease, specifically myocardial infarction (Mi), have been intensively evaluated. results from two large cohort studies (Data collection on adverse events of anti-HiV Drugs and the Strategies for Management of antiretroviral therapy) suggest an increased risk of Mi with current or recent, but not cumulative, use of abacavir. 2, 3 More recent observational studies have also shown an increased risk of Mi associated with abacavir, 4-6 while others have not. 7, 8 in contrast, meta-analyses of randomized controlled trials (rcts) have not shown the same increased risk. [9] [10] [11] Furthermore, cohort studies have demonstrated an association between cumulative exposure to first-generation protease inhibitors and Mi-likely related to effects these medications have on lipid profiles. 12 Some of the observed increased risk of Mi among patients exposed to abacavir in observational studies may be attributed to confounding; patients prescribed abacavir were at a higher baseline risk of comorbid conditions that increase the risk of cardiovascular disease. 7 Many of the studies demonstrating an increased risk include prevalent users of antiretroviral medications. inclusion of prevalent users makes it difficult to distinguish true confounders from clinical conditions affected by prior treatment and the underascertainment of events, particularly if the events occur early in treatment. 14 Furthermore, these observational studies used different comparison groups rendering it difficult to compare the results. While rcts may not be subject to the same biases as observational studies, the shorter cumulative follow-up times and younger, healthier populations may reduce the power to detect a difference between treatment groups.
to address the discrepancy between observational studies and meta-analyses of rcts, it is important to design an observational study that would mimic an rct. 15 the use of a first-treatment-carried-forward (intention-to-treat in an rct), new-user, active-comparator design attempts to define study cohorts with treatment equipoise, thus reducing the potential for confounding and selection bias. We used this type of cohort study design to examine the effects of initiating specific antiretroviral therapies on the risk of Mi among previously untreated HiV-infected patients receiving cart. Our study included three comparison groups (study arms): (1) tenofovir compared with abacavir, (2) atazanavir compared with nonnucleoside reverse transcriptase inhibitors (nnrtis), and (3) lopinavir compared with nnrtis ( Figure 1a , B).
METHODS

Data Source and Study Population
We implemented this cohort study using north carolina (nc) Medicaid administrative data obtained for the years 2002-2008. the Medicaid program is state and federally funded to provide health-care benefits to persons with low income. the data contain health-care service reimbursement information, including that which is recorded for beneficiaries who are also eligible for Medicare. 16 to be eligible for this study, patients had to (1) be ≥18 years of age, (2) be HiV-infected, based on administrative criteria (International Classification of Diseases, 9th Revision [ICD-9] code 042.xx or a claim for one of the 26 FDa-approved antiretroviral medications), (3) have at least 180 days of Medicaid eligibility before study entry, and (4) be new recipients of a cart regimen. a regimen was defined as a group of antiretrovirals dispensed on the same day. a cart regimen contains (1) two nucleoside/nucleotide reverse transcriptase inhibitors (nrtis) as a backbone, and (2) an anchor antiretroviral that is either an nnrti, a protein inhibitor (Pi) boosted or unboosted with ritonavir (an integrase strand transfer inhibitor [iSti]), or an additional nrti. For this study, we considered only cart regimens containing lamivudine or emtricitabine as one of the two nrtis in the backbone, given that all preferred initial treatment regimens include one of these agents. 17 the second nrti was either abacavir or tenofovir. a new cart regimen recipient was defined as a patient receiving a cart regimen with all medications started on the same day, without a prescription filled for any antiretroviral in the 180 days before study entry, with the exception of <30 days of a non-cart regimen (eg, monotherapy or dual therapy). We excluded new recipients with a regimen dispensed for <30 days followed by a nonstandard cart regimen and patients with any claims for Mi (acute or chronic), coronary artery bypass graft, or percutaneous transluminal coronary angioplasty in the 180 days before cart initiation. For all analyses, we excluded patients on regimens that contained both the exposed (treated) and the active-comparator antiretroviral (eg, abacavir and tenofovir).
Exposure and Outcome Definitions
Our primary outcome was Mi, defined in the Medicaid data by a diagnosis code of 410.xx in any position and a length of stay ≥1 day. this algorithm was previously validated in the nc Medicaid population (sensitivity = 0.765 [95% confidence interval (ci) = 0.501-0.932]; specificity = 0.989 [0.980-0.994]). 18 We first considered patients who had not previously received the most common nrtis, abacavir and tenofovir. next, we considered patients who had not previously received atazanavir (boosted and unboosted with ritonavir) or lopinavir-ritonavir separately from nnrtis.
Confounder and Covariates
We identified potential confounders of the antiretroviral use-Mi relationship based on expert knowledge about the relationship of these factors with the exposure and the outcome. We obtained data on potential confounders from the Medicaid data in the 180 days before cart initiation. We included age at study entry, sex, race, calendar year of antiretroviral initiation (six indicator variables for calendar year), concomitant cardiovascular medication use (angiotensin-converting enzyme [ace] receptor inhibitors, angiotensin receptor blocking agents, beta-receptor blocking agents, calcium channel receptor blocking agents, and 3-hydroxy-3-methyl-glutaryl-coa reductase inhibitors), comorbidities in the 180 days before cart initiation (based on ICD-9 codes from the Deyo implementation of the charlson comorbidity score, 19 used separately, ie, not as a score), number of hospitalizations in the 180 days before cart initiation (0, 1-2, >2), and number of medication claims in the 180 days before cart initiation (0, 1-15, 15-20, >20 medications). For the nrti comparative analysis, we considered regimen type based on anchor antiretroviral (ritonavir-boosted Pi-or iSti-based, nnrti-based, ritonavir-unboosted Pi-based, triple nrti-based).
Statistical Analysis
to account for baseline differences in treatment, we used a form of inverse probability weighting methodology. inverse probability weighting relies on the propensity score, calculated as the conditional probability of receiving active treatment. as we were interested in estimating the average treatment effect in three active treatment populations, we weighted the data to create a pseudopopulation of patients with the same distribution of patient characteristics as patients initiating tenofovir for the nrti comparison and the same as patients initiating atazanavir or lopinavir-ritonavir for the nnrti/Pi comparisons. Patients receiving tenofovir, atazanavir, or lopinavir-ritonavir received a weight of 1 and patients receiving abacavir or an nnrti received a weight defined as ê(X)/(1 − ê(X)) where ê(X) is the propensity score. 20, 21 Before creating the weighted pseudopopulations, we trimmed nonoverlapping regions of the propensity score distributions to exclude patients with characteristics that had a zero probability of initiating one of the drugs compared (nonpositivity).
Follow-up started on the day of the collection of claims for the new cart regimen and continued until the occurrence of (1) Mi, (2) discontinuation of Medicaid eligibility, or (3) end of study period (31 December 2008), whichever came first. We calculated overall unadjusted incidence rates for Mi using Poisson regression. We then used inverse probability weights to create adjusted Kaplan-Meier curves for each of the study comparison groups. Finally, we created cox proportional hazard regression models to examine unadjusted and inverse probability-weighted hazard ratios (Hrs) and corresponding 95% cis to evaluate the effect of each active treatment in the treated populations. For weighted analyses, we used robust variance estimation. Point estimates and associated 95% cis for risk differences were derived from 500 bootstraps of weighted data. this study was approved by the University of north carolina irB. analyses were conducted using SaS, Version 9.2 (SaS institute, cary, nc) or Stata Statistical Software, release 11 (Statacorp, college Station, tX).
Sensitivity Analyses
We conducted sensitivity analyses to address treatment switch or discontinuation and unmeasured confounding. We censored patients (1) at the first Mi, (2) stopping or switching antiretrovirals, or (3) subject to administrative censoring. We also evaluated Kaplan-Meier curves for time-to-treatment switch or discontinuation, stratified by treatment. We used established methodology to assess the role of unmeasured confounding on our results. 22 
RESULTS
Study Population and Descriptive Statistics
Between 1 January 2002 and 31 December 2008, 13,006 HiV-positive beneficiaries enrolled in nc Medicaid. Of these, 3500 beneficiaries were new recipients of a qualifying cart regimen ( Figure 2 ). Overall, the distribution of patient characteristics receiving an initial cart regimen was similar to those of the overall HiV patient population; however, the Medicaid population represents a larger proportion of HiV-infected women. Of the 10,082 patients prescribed antiretrovirals, 18% received regimens containing two nrtis and an nnrti. this also was the predominant regimen type among initial cart recipients (33%).
the distribution of patient characteristics among new recipients of cart was generally similar among recipients of specific antiretrovirals. We noted differences in comorbidities, regimen type, and year of antiretroviral initiation among recipients of abacavir or tenofovir (table 1) . Based on ICD-9 codes, a greater proportion of abacavir recipients had renal disease at baseline (5% vs. 2%). conversely, a larger proportion of tenofovir recipients had mild liver disease (4% vs. 2%) and a diagnosis of cancer (5% vs. 4%). Most abacavir recipients initiated cart before 2006 (60%), whereas many tenofovir recipients initiated cart during or after 2006 (64%) (table 1). Baseline characteristics of patients receiving atazanavir, lopinavir, or nnrtis were generally similar (table 2).
Comparative Safety Results
Overall, patients contributed 6399 person-years and experienced 38 Mi events. the unadjusted incidence rate of Mi for the entire new cart population was 5.9 (95% ci = 4.3-8.2) per 1000 person-years of follow-up. Unadjusted incidence rates for each of the study groups are displayed in table 3. Patients initiating abacavir or tenofovir had an unadjusted incidence rate of 11.9 (95% ci = 7.2-19.7) and 4.5 (2.5-8.2) per 1000 person-years of follow-up (table 3) .
Unadjusted cox proportional hazard regression models showed an increased Hr of Mi among recipients of abacavir compared with tenofovir (Hr = 2.70 [95% ci = 1.24-5.91]). if all those who actually initiated tenofovir had initiated abacavir instead, these patients would have been twice as likely to have an Mi. However, the Hr point estimate was closer to the null and less precise when compared with the crude (Hr = 2.05 [0.72-5.86]). Figures 3 and 4 display Kaplan-Meier curves for the inverse probability-weighted pseudopopulations for each of the study groups stratified by active or comparator antiretroviral. the absolute difference in Mi risk at 5 years after cart initiation for those receiving abacavir compared with tenofovir was 3.5 per 100 (95% ci = -1.6 to 8.6). Unadjusted and inverse probability-weighted models did not demonstrate clinically meaningful differences in Hrs of Mi among the other comparison groups (table 3) .
Sensitivity Analyses
to address treatment switch or discontinuation, we attempted an analysis similar to a per-protocol analysis in an rct; however, we did not have an adequate number of events to address this question. among patients receiving cart regimens containing abacavir, the median time to regimen switch or discontinuation was 34 days compared with 58 days among patients receiving cart containing tenofovir (log-rank P = 0.01). Patients initiating cart containing an nnrti remained on their initial cart regimen longer than those initiating cart containing atazanavir or lopinavir-ritonavir (P value all < 0.01) (Figure 5a-c) . a sensitivity analysis evaluating the potential impact of unmeasured confounding demonstrated that the magnitude of an association between an unmeasured confounder and initiation of specific cart, as well as the association between the same unmeasured confounder and Mi, would need to be very large to reduce the observed Hr from 2.05 to 1.0 (eFigure 1, http://links.lww.com/eDe/a746).
DISCUSSION
We simulated three active comparison rcts by including patients who were initiating specific antiretroviral medications as a part of guideline-recommended cart. this study design allowed us to evaluate the effects of initial treatment with specific antiretroviral medications on the risk of Mi. We found that patients treated initially with abacavir as part of a new cart regimen-but not atazanavir or lopinavir-had an increased rate of Mi when compared with patients treated initially with tenofovir or an nnrti.
there are proposed biological mechanisms for an increased rate of Mi among patients exposed to abacavir, although the exact underlying pathophysiology remains unclear. HiV infection influences factors related to inflammation and endothelial function, [23] [24] [25] [26] and initiation of antiretroviral therapy generally improves these factors. [26] [27] [28] conversely, treatment with abacavir may impair endothelial function and increase inflammation. However, results are conflicting. [29] [30] [31] More recent evidence suggests that abacavir increases platelet reactivity, thus increasing Mi risk. 32, 33 the risk of Mi over the 5-year period observed in our data was 3%. Kowalska and colleagues 34 calculated 5-yearpredicted Mi risks for varying risk categories using the Data collected on adverse events of anti-HiV Drugs study. Patients who smoked and had high lipid levels had a predicted risk of Mi at 5 years, similar to that observed in our study. there are more men in the Kowalska et al study than in the HiV-infected Medicaid population, however. the ageand sex-standardized 5-year Mi risk of persons who smoke and have a high cholesterol ratio in the Framingham study is lower (0.8%) than we observed. 35 We would expect a higher Propensity score based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days before antiretroviral initiation, cardiovascular drug use in the 180 days before antiretroviral initiation, hospitalization in the 180 days before antiretroviral initiation, regimen type, and year of initiation (six indicator variables for year). the median propensity scores for the receipt of abacavir and tenofovir were 0.60 (iQr: 0.15-0.82; full range: 0.02-0.92) and 0.84 (iQr: 0.78-0.88; full range: 0.15-0.97), respectively. Forty-nine patients who had characteristics that were always associated with abacavir (n = 1) or tenofovir (n = 48) initiation were excluded from weighted analysis. after trimming of nonoverlap in the propensity score distributions, iP weights used to estimate the effect of initiation of cart regimens containing abacavir compared with tenofovir ranged from 0.02 to 12.0. b numbers in cell <11 (cannot be presented based on data use agreement with north carolina Medicaid). cells <11 presented for pseudopopulation as persons could be represented more than once. c comorbidities include heart failure, peripheral vascular disease, cerebrovascular disease, mild liver disease, moderate/severe liver disease, renal disease, diabetes (uncomplicated), diabetes (complicated), cancer, metastatic carcinoma, connective tissue disease, chronic pulmonary disease, and dementia. comorbidities with >11 subjects in at least one cell of the baseline population presented. d angiotensin receptor blocking agent percentages not presented as there was at least one cell in the baseline population that had <11 subjects. HMg-coa indicates 3-hydroxy-3-methyl-glutaryl-coa; iSti, integrase strand transfer inhibitor; na, not available; nnrti, nonnucleoside reverse transcriptase inhibitor; nrti, nucleoside reverse transcriptase inhibitor; Pi, protease inhibitor. risk of Mi in our population than in the general population. it is plausible that the risk to patients enrolled in the Data collected on adverse events study is similar to that in our own study, given that our Medicaid cohort (which despite having a higher proportion of women) would reflect the increased risk that comes with low socioeconomic status. 36 the observed Hrs point estimates comparing the use of abacavir to tenofovir are consistent with (although slightly Propensity score used to create inverse probability weights to estimate the treatment effect in the three treatment groups based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days before antiretroviral initiation, cardiovascular drug use in the 180 days before antiretroviral initiation (statin calcium channel blocker, betablocker, ace inhibitor), hospitalization in the 180 days before antiretroviral initiation, regimen type (nnrti, boosted Pi/integrase strand transfer inhibitor, unboosted Pi, triple nrti), and year of initiation (six indicator variables for year). c reference category. d Propensity score used to create inverse probability weights based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days before antiretroviral initiation (0, 1-15, 15-20, >20), cardiovascular drug use in the 180 days before antiretroviral initiation (statin, calcium channel blocker, beta-blocker, ace inhibitor), hospitalization in the 180 days before antiretroviral initiation (0, 0-2, >2), and year of initiation (six indicator variables for year).
Year of antiretroviral initiation Propensity scores based on the following characteristics: age, race, sex, comorbidities, drug use in the 180 days before antiretroviral initiation, cardiovascular drug use in the 180 days before antiretroviral initiation, hospitalization in the 180 days before antiretroviral initiation, and year of initiation (indicators for year of initiation). the median propensity scores for the receipt of atazanavir or an nnrti were 0.30 (iQr: 0.25-0.37; full range: 0.02-0.65) and 0.25 (iQr: 0.18-0.33; full range: 1 × 10 -7 -0.60). Of patients that received either atazanavir or an nnrti, we trimmed 54 patients who had characteristics that were always associated with initiation of atazanavir (n = 6) or nnrti (n = 48). inverse probability weights used to estimate the effect of initiation of cart regimens containing atazanavir or an nnrti and Mi ranged from 0.02 to 1.836. the median propensity scores for the receipt of lopinavir-ritonavir or an nnrti were 0.34 (iQr: 0.25-0.34; full range: 0.10-0.75) and 0.27 (iQr: 0.20-0.36; full range: 0.06-0.70). We trimmed 24 patients who had characteristics that were always associated with initiation of lopinavir-ritonavir (n = 2) or an nnrti (n = 22). inverse probability weights used to estimate the effect of initiation of cart regimens containing lopinavir-ritonavir or an nnrti and Mi ranged from 0.11 to 2.35. b numbers in cell <11 cannot be presented based on data use agreement with nc Medicaid. cells <11 presented for pseudopopulation as persons could be represented more than once. c comorbidities include heart failure, peripheral vascular disease, cerebrovascular disease, mild liver disease, moderate/severe liver disease, renal disease, diabetes (uncomplicated), diabetes (complicated), cancer, metastatic carcinoma, connective tissue disease, chronic pulmonary disease, and dementia. comorbidities with ≥11 subjects in at least one cell presented. d angiotensin receptor blocking agent percentages not presented as all cells had <11 subjects. na indicates not available; HMg-coa, 3-hydroxy-3-methyl-glutaryl-coa. higher than) results from other observational studies on abacavir and Mi. 2, [4] [5] [6] Our results do not concur with results from clinical trials. the 95% ci for the Hr in our study overlaps the null, and we thus cannot exclude chance as an alternative explanation. nonetheless, the magnitude of the adjusted Hr speaks against residual and unmeasured confounding as alternative explanations. We did observe that trimming the upper tails of the propensity score distribution for abacavir versus tenofovir treatment attenuated the Hr, which may suggest that treatment heterogeneity may be present, with the potential to influence our results. in general, rcts aim to establish efficacy, whereas observational studies evaluate effectiveness and safety; the mere enrollment and follow-up in an rct may result in different outcomes than would occur among patients followed in a general clinical setting. Patients enrolled in rcts are often healthier and have a lower risk of comorbidities. 37, 38 Disparate conclusions from meta-analyses and observational studies may be due to differing lengths of follow-up and overall characteristics of the study population. the average length of follow-up in the rcts was much longer than in our study (591 vs. 38 days). 11 However, the total person-time of follow-up in our study was greater; patients included in the abacavir-tenofovir analysis contributed a combined 3697 person-years of follow-up compared with an average 719 person-years among the collective rcts in the FDa-sponsored meta-analysis. 11 this meta-analysis did not consider the length of follow-up when calculating the summarized risk difference, making the interpretation of those results more difficult.
Some observational studies evaluating the risk of Mi among patients prescribed abacavir demonstrated evidence of confounding and effect modification. 6 Using a large cohort of military veterans, Bedimo et al 8 showed that the observed relationship between abacavir use and Mi may be due to differential prescribing. Patients with baseline comorbidities that increase the risk of Mi, such as chronic kidney disease, were more likely to receive abacavir. However, an observational study conducted using the same veterans database found an association between abacavir and Mi, with less evidence of confounding due to baseline kidney dysfunction. 7 We also noted baseline differences in comorbidities between antiretroviral exposure groups. We addressed these known baseline clinical differences through inverse probability weighting and showed that this approach successfully balanced differences in cardiovascular risk factors within each of the treatment groups. One main concern regarding the use of administrative data is the inability to obtain information on potentially important confounding variables (such as cD4 count, HiV rna, lDl cholesterol, and history of smoking) that may be related to treatment assignment and Mi. therefore, it is possible that our findings could be subject to unmeasured confounding. Our study design limits the potential for unmeasured confounding by both indication (likely similar for the treatment regimens compared) and frailty. [39] [40] [41] Using the available variables in the data to create inverse probability weights, we anticipate that these unmeasured factors are likely balanced. However, we cannot confirm this. research on frailty has shown that older or terminally ill patients with substantial comorbidity may be undertreated due to the expectation of shortened life expectancy. 41, 42 We considered only specific cart regimens that contained lamivudine or emtricitabine, which may have reduced our sample size. Furthermore, follow-up time was relatively short, resulting in reduced numbers of Mi events and low precision of estimates. a limited sample of patients initiating atazanavir and lopinavir constrained our ability to detect a difference between these groups. Finally, due to inadequate sample size, we were unable to conduct an analysis of treatment stop and discontinuation. this type of analysis would allow us to avoid bias from treatment changes during followup but at the price of introducing the potential for selection bias-which we avoid in our first-treatment-carried-forward analysis. With adequate sample size, both a first-treatmentcarried-forward analysis and an analysis of treatment stop and discontinuation would give us the ability to assess the impact of selection and attrition bias on our results.
another concern with administrative data is the potential for medication exposure misclassification. recently, Medicaid agencies in new York, Florida, and Pennsylvania reported that some patients sold antiretrovirals and other chronic disease medications received through Medicaid on the black market. 43 if this had occurred in nc during our study period, we would expect the misclassification to be nondifferential. However, to our knowledge, this activity was not prevalent in this state. it should also be noted that, while those included in this study had not received antiretroviral medication in the previous 6 months via Medicaid (which we used as a surrogate for antiretroviral naive status), some patients may have had unobserved previous antiretroviral exposures. We do not believe that the inclusion of nonnaive patients would have a substantial impact on our results. nonetheless, the concern warrants further investigation, either by expanding the period of required Medicaid eligibility before antiretroviral initiation or by linking the administrative data to a more comprehensive clinical record. Furthermore, we were unable to determine reasons for lack of eligibility and therefore unable to discern losses to follow-up and death, as both these instances would result in loss of Medicaid eligibility.
the new-user design is often used for comparative safety and effectiveness research, as it allows for the ascertainment of events that may have occurred early after treatment initiation and limits the potential for confounding. 14, 39 Preferential prescribing of one cart regimen or another regimen based on comorbidities (as described above) is unlikely to be as important when considering patients receiving second-or third-line treatments, which are often included in a prevalent-user study. However, the choice of initial cart is likely linked to future treatment decisions, rendering the new-user design relevant when assessing antiretroviral treatment outcomes. Finally, this study design allows for the assessment of confounders at the time of antiretroviral initiation, thus reducing the influence of time-dependent confounders on the causal pathway. 15 We used an active-comparator, new-user design, in combination with a first-treatment-carried-forward analysis and a validated algorithm, for identifying Mi. to our knowledge, this type of study design has not previously been used to examine the relationship between antiretroviral use and Mi. Studies completed to date have defined exposure to specific antiretrovirals as "any/recent/cumulative" use and compared these definitions to no use of the antiretroviral in question. 2, [4] [5] [6] 8 While important, these types of comparisons make it difficult to compare across studies, particularly studies relating to HiV, as "no-use" is likely to equate to the use of some other antiretroviral that differs by study. this heterogeneity of comparison group makes generalization across populations difficult, as treatment patterns may differ. While the Data collection on adverse events of anti-HiV Drugs study 2 and other clinical cohort collaborations have superior sample size and follow-up, our study design is unique and our results are potentially more generalizable to patients receiving regular clinical care in the United States. in addition, almost half of our study population were women, whereas other observational studies have included between 2% and 27% women. [2] [3] [4] [5] 8, [10] [11] [12] this further improves the generalizability of our results.
Despite the limitations of our study and those inherent in all observational studies, such as unmeasured confounding, our results demonstrate an increased risk of Mi among patients initiating abacavir compared with tenofovir as part of a standard cart regimen. to confirm these findings, future studies should use active-comparator designs and include more HiV-infected patients initiating cart, as well as information on important confounding factors not available in administrative data.
